David BA - GlucoTrack CoFounder
| GCTK Stock | USD 0.25 0.01 3.85% |
Insider
David BA is CoFounder of GlucoTrack
| Age | 59 |
| Address | 301 Route 17 North, Rutherford, NJ, United States, 07070 |
| Phone | 201 842 7715 |
| Web | https://glucotrack.com |
GlucoTrack Management Efficiency
The company has return on total asset (ROA) of (1.575) % which means that it has lost $1.575 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.4113) %, meaning that it created substantial loss on money invested by shareholders. GlucoTrack's management efficiency ratios could be used to measure how well GlucoTrack manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -1.52. Return On Capital Employed is expected to rise to -1.99 this year. At this time, GlucoTrack's Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 69.9 K this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 3.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Myers | Predictive Oncology | 67 | |
| Wang Xin | Meihua International Medical | 35 | |
| Raymond Vennare | Predictive Oncology | 71 | |
| Robert MBA | Predictive Oncology | 69 | |
| Yulin Wang | Meihua International Medical | 55 | |
| Pr DSc | Microbot Medical | 72 | |
| Rachel Vaknin | Microbot Medical | 45 | |
| Eyal MD | Microbot Medical | 59 | |
| Julia Kirshner | Predictive Oncology | N/A | |
| DSc OD | Predictive Oncology | N/A | |
| Barry Berler | Sharps Technology | 70 | |
| Andrew CPA | Sharps Technology | 68 | |
| Alan Blackman | Sharps Technology | 75 | |
| David Stefansky | Nexgel Inc | 53 | |
| Keith Schaefer | Avinger | N/A | |
| Lianzhang Zhao | Meihua International Medical | 56 | |
| Robert Hayes | Sharps Technology | 57 | |
| Steven MD | Sharps Technology | 62 | |
| BS BSc | Predictive Oncology | 73 | |
| Adam III | Nexgel Inc | 47 | |
| Theresa Ferguson | Predictive Oncology | N/A | |
Management Performance
| Return On Equity | -5.41 | ||||
| Return On Asset | -1.57 |
GlucoTrack Leadership Team
Elected by the shareholders, the GlucoTrack's board of directors comprises two types of representatives: GlucoTrack inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlucoTrack. The board's role is to monitor GlucoTrack's management team and ensure that shareholders' interests are well served. GlucoTrack's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlucoTrack's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erez BenZvi, GM Product | ||
| Drinda Benjamin, Vice Marketing | ||
| Paul Goode, Chief Officer | ||
| MScEE MBA, Chairman CoFounder | ||
| Mark Tapsak, Vice Technology | ||
| Esq CPA, Chief Officer | ||
| David BA, CoFounder | ||
| James Thrower, Vice Engineering | ||
| James Cardwell, Chief Officer |
GlucoTrack Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlucoTrack a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.41 | ||||
| Return On Asset | -1.57 | ||||
| Current Valuation | 3.95 M | ||||
| Shares Outstanding | 8.21 M | ||||
| Shares Owned By Insiders | 34.97 % | ||||
| Shares Owned By Institutions | 0.95 % | ||||
| Number Of Shares Shorted | 257.74 K | ||||
| Price To Book | 21.40 X | ||||
| Gross Profit | (20 K) | ||||
| EBITDA | (7.09 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.91) | Return On Assets (1.57) | Return On Equity (5.41) |
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.